A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)
SurfSubQ - A Prospective Longitudinal Multicenter Observational Study to Investigate Neurofilament Light Chain Levels and Patient Satisfaction After Subcutaneous Ocrelizumab Administration in Persons With Multiple Sclerosis
Hoffmann-La Roche
842 participants
Sep 26, 2024
OBSERVATIONAL
Conditions
Summary
The main purpose of the study is to evaluate participant satisfaction after administration of ocrelizumab subcutaneous (SC) after 12 months using the therapy administration satisfaction questionnaire subcutaneous (TASQ-SC).
Eligibility
Inclusion Criteria3
- Diagnosis of MS
- RMS and PPMS participants diagnosed according to the McDonald criteria of 2017
- First treatment during the course of MS therapy with ocrelizumab SC according to the local prescribing information, regardless of the reason for starting treatment with ocrelizumab
Exclusion Criteria5
- Participation in interventional studies investigating DMTs for MS
- Prior or simultaneous participation in CONFIDENCE or MoOzaRt (ISRCTN55332718) non interventional study (NIS) at the same study site
- Prior treatment with rituximab (MabThera®) or ublituximab (Briumvi®)
- Severe psychiatric disability
- Pregnant women
Interventions
Ocrelizumab will be administered as SC injection as per discretion of the treating physician in accordance with local clinical practice and local labeling.
Locations(74)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06780150